Back to today’s briefing

Story perspectives

Moderna and Merck’s Keytruda Combo Extends Melanoma Recurrence-Free Survival

8/22/2026

31 3 Full Breakdown

Summary

Story summary

Moderna and Merck reported their vaccine-Keytruda combo reduced melanoma recurrence in a Phase 3 trial.
The study enrolled 1,137 high-risk stage IIB-IV melanoma patients who had surgery.
Patients receiving the combo achieved longer recurrence-free survival.
The combo also met the secondary endpoint of distant metastasis-free survival.
Side effects were mild to moderate with no new safety concerns.

1 of 1

Story summary

Moderna and Merck reported their vaccine-Keytruda combo reduced melanoma recurrence in a Phase 3 trial.
The study enrolled 1,137 high-risk stage IIB-IV melanoma patients who had surgery.
Patients receiving the combo achieved longer recurrence-free survival.
The combo also met the secondary endpoint of distant metastasis-free survival.
Side effects were mild to moderate with no new safety concerns.